Bifogade filer
Herantis Pharma To Participate In Sept Conf ENG
Kurs
-5,06%
Likviditet
0,01 MEUR
Prenumeration
Kalender
| Tid* | ||
| 2025-08-21 | 07:00 | Kvartalsrapport 2025-Q2 |
| 2025-04-24 | N/A | Årsstämma |
| 2025-03-06 | 07:00 | Bokslutskommuniké 2024 |
| 2024-08-22 | - | Kvartalsrapport 2024-Q2 |
| 2024-04-25 | - | X-dag ordinarie utdelning HRTIS 0.00 EUR |
| 2024-04-24 | - | Årsstämma |
| 2024-03-06 | - | Bokslutskommuniké 2023 |
| 2023-11-17 | - | Extra Bolagsstämma 2023 |
| 2023-08-24 | - | Kvartalsrapport 2023-Q2 |
| 2023-04-21 | - | X-dag ordinarie utdelning HRTIS 0.00 EUR |
| 2023-04-20 | - | Årsstämma |
| 2023-03-02 | - | Bokslutskommuniké 2022 |
| 2022-08-25 | - | Kvartalsrapport 2022-Q2 |
| 2022-04-22 | - | X-dag ordinarie utdelning HRTIS 0.00 EUR |
| 2022-04-21 | - | Årsstämma |
| 2022-03-03 | - | Bokslutskommuniké 2021 |
| 2021-08-26 | - | Kvartalsrapport 2021-Q2 |
| 2021-04-16 | - | X-dag ordinarie utdelning HRTIS 0.00 EUR |
| 2021-04-15 | - | Årsstämma |
| 2021-03-03 | - | Bokslutskommuniké 2020 |
| 2020-12-02 | - | Extra Bolagsstämma 2020 |
| 2020-08-27 | - | Kvartalsrapport 2020-Q2 |
| 2020-04-09 | - | X-dag ordinarie utdelning HRTIS 0.00 EUR |
| 2020-04-08 | - | Årsstämma |
| 2020-02-27 | - | Bokslutskommuniké 2019 |
| 2019-08-28 | - | Kvartalsrapport 2019-Q2 |
| 2019-04-12 | - | X-dag ordinarie utdelning HRTIS 0.00 EUR |
| 2019-04-11 | - | Årsstämma |
| 2019-03-12 | - | Extra Bolagsstämma 2019 |
| 2019-02-28 | - | Bokslutskommuniké 2018 |
| 2018-08-29 | - | Kvartalsrapport 2018-Q2 |
| 2018-04-12 | - | X-dag ordinarie utdelning HRTIS 0.00 EUR |
| 2018-04-11 | - | Årsstämma |
| 2018-03-02 | - | Bokslutskommuniké 2017 |
| 2017-11-09 | - | Extra Bolagsstämma 2017 |
| 2017-08-29 | - | Kvartalsrapport 2017-Q2 |
| 2017-04-12 | - | X-dag ordinarie utdelning HRTIS 0.00 EUR |
| 2017-04-11 | - | Årsstämma |
| 2017-02-28 | - | Bokslutskommuniké 2016 |
| 2016-08-25 | - | Kvartalsrapport 2016-Q2 |
| 2016-04-12 | - | X-dag ordinarie utdelning HRTIS 0.00 EUR |
| 2016-04-11 | - | Årsstämma |
| 2016-02-25 | - | Bokslutskommuniké 2015 |
| 2015-08-19 | - | Kvartalsrapport 2015-Q2 |
| 2015-04-10 | - | X-dag ordinarie utdelning HRTIS 0.00 EUR |
| 2015-04-09 | - | Årsstämma |
| 2015-02-27 | - | Bokslutskommuniké 2014 |
| 2014-04-23 | - | Kvartalsrapport 2014-Q1 |
| 2014-03-05 | - | Bokslutskommuniké 2013 |
Beskrivning
| Land | Finland |
|---|---|
| Lista | First North Finland |
| Sektor | Hälsovård |
| Industri | Läkemedel & Handel |
Herantis Pharma Plc | Press Release | September 04, 2023 at 17:10:00 EEST
Herantis Pharma Plc, Press Release, 4 September 2023 at 17:10 EEST
Herantis Pharma Plc (“Herantis”), a clinical-stage biotechnology company developing disease modifying therapies for Parkinson’s disease, today announced that Herantis will participate in the following conferences in September 2023:
Sachs 23rd Annual Biotech in Europe Forum
Dates: September 20th - 21st, 2023
Location: Basel, Switzerland
1:1 meetings and company presentation.
CEO, Antti Vuolanto will participate in a panel discussion at Sachs, September 20th, 17:10 CEST.
Topic: Advances in Approaches to Neurological Disorders
Co-Chaired by:
Jenny Laird, VP, Search & Evaluation Neuroscience, Eli Lilly and Company
Henrik Sindal Jensen, Senior Director, Corporate Business Development & Strategy, H. Lundbeck A/S
ØU Life Science Investor Conference
Dates: September 27th, 2023
Location: Copenhagen, Denmark
CEO, Antti Vuolanto will give a company presentation at 14:05-14:35 CEST.
If you want a 1:1 meeting with Herantis, you can connect with us directly at ir@herantis.com.
Contacts
For more information, please contact:
Julie Silber/Gabriela Urquilla
Tel: +46 (0)7 93 486 277/+46 (0)72-396 72 19
Email: ir@herantis.com
Certified Advisor: UB Securities Ltd, Finland: +358 9 25 380 225
About Us
About Herantis Pharma Plc
Herantis Pharma Plc is a clinical-stage biotechnology company developing disease modifying therapies for Parkinson’s disease. Herantis’ lead product HER-096, is an advanced small synthetic chemical peptidomimetic molecule developed based on the active site of the parent CDNF protein. It combines the compelling mechanism of action of the CDNF protein with the convenience of subcutaneous administration. The ongoing Phase 1a clinical study will assess safety, tolerability, and blood-brain barrier penetration of subcutaneously administered HER-096. Top-line data is expected by the end of 2023.
The shares of Herantis are listed on the Nasdaq First North Growth Market Finland.
Company website: www.herantis.com